<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Family Reprod Health</journal-id><journal-id journal-id-type="iso-abbrev">J Family Reprod Health</journal-id><journal-id journal-id-type="publisher-id">JFRH</journal-id><journal-title-group><journal-title>Journal of Family &#x00026; Reproductive Health</journal-title></journal-title-group><issn pub-type="ppub">1735-8949</issn><issn pub-type="epub">1735-9392</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27385973</article-id><article-id pub-id-type="pmc">4930453</article-id><article-id pub-id-type="publisher-id">JFRH-10-42</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hossein-Rashidi</surname><given-names>Batool</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Khandzad</surname><given-names>Bahareh</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shahrokh-Tehraninejad</surname><given-names>Ensieh</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bagheri</surname><given-names>Maryam</given-names></name><degrees>M.Sc.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gorginzadeh</surname><given-names>Mansoureh</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>2</label>Tehran University of Medical Sciences, Tehran, Iran</aff><author-notes><corresp id="cor">Correspondence: Mansureh Gorginzadeh, Tehran University of Medical Sciences, Tehran, Iran.<email>m_g802002@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2016</year></pub-date><volume>10</volume><issue>1</issue><fpage>42</fpage><lpage>48</lpage><history><date date-type="received"><month>9</month><year>2015</year></date><date date-type="rev-recd"><month>3</month><year>2016</year></date><date date-type="accepted"><month>3</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<bold>Objective:</bold> Since there is still controversy regarding the best first-line choice for ovulation induction (OI) other than clomiphene citrate (CC) in infertile women diagnosed with polycystic ovary syndrome (PCOS), the aim of the present study was to compare recombinant human FSH with CC as the first course of OI in these women. </p><p>
<bold>Materials and methods:</bold> In this pilot randomized controlled trial, 104 infertile women diagnosed with PCOS were randomized in two groups to receive either CC with the dose of 100mg per day from day 3 of a spontaneous or progestin-induced menstruation for 5 days or rFSH with the starting dose of 50 IU daily {and weekly dose increment of as low as 12.5 IU}, on the day4 of the cycle. They were assessed during a single OI course. The pregnancy rate (PR) and live birth rate (LBR) were the primary outcomes. The follicular response, endometrial thickness, cancellation of the cycles and ovarian hyper stimulation (OHSS) rate were the secondary outcomes.</p><p>
<bold>Results:</bold> Analyzing data of 96 patients using Chi<sup>2 </sup>and Fischer&#x02019;s Exact test (44 in rFSH group and 52 in CC group), both PR and LBR were comparable in the two groups {13.6% vs. 9.6% and 11.4% vs. 9.6% respectively}, with the difference not to be significant (p &#x0003e; 0.05). No cases of OHSS or multiple gestations happened during the treatment course.</p><p>
<bold>Conclusion:</bold> It seems that rFSH is as efficacious as CC while not with more complications for the first-line OI in infertile women with PCOS. However, due to the limitations of the present study including the small population and the single cycle of treatment, our results did not come out to prove this and more studies with larger study population are needed to compare the cumulative PR and LBR.</p></abstract><kwd-group><title>Key Words</title><kwd>Polycystic Ovary Syndrome</kwd><kwd>Clomiphene Citrate</kwd><kwd>Recombinant FSH</kwd><kwd>Ovulation Induction</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Being the most common endocrine disorder in women, polycystic ovary syndrome (PCOS) is also the leading cause of anovulatory infertility. The higher prevalence of PCOS in Asian countries compared to Western ones on one hand and the higher desire for pregnancy in these countries on the other hand further raise the importance of this issue (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>).</p><p>What is already practiced for the treatment of infertility in women with PCOS is the use of clomiphene citrate (CC) as the first modality, and for those who do not ovulate or conceive after maximum six cycles, second-line therapy including combined treatment with CC and metformin is applied (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Gonadotropins are used as the third-line strategy (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Addition of IUI in order to increase the pregnancy rates though accompanied by extra laboratory work, more hospital visits and further costs has also been recommended (<xref rid="B7" ref-type="bibr">7</xref>). In those infertile PCOS patients who are not responsive to the previous therapies, IVF is regarded as the last resort (<xref rid="B2" ref-type="bibr">2</xref>). CC results in ovulation in 75% of anovulatory women; however, pregnancy rate is regarded to be as low as 36% (<xref rid="B6" ref-type="bibr">6</xref>). Anti-estrogenic effects of CC on endometrium and cervical mucus are mainly blamed for this difference (<xref rid="B6" ref-type="bibr">6</xref>). Therefore, CC does not seem to be as efficient as beforeand this may be due to the emergence of clomiphene failure and resistance (<xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Some disadvantages have rendered gonadotropins as the second-line modality and not the first for ovulation induction (OI) in PCOS. These mainly include multi follicular development and high cancellation rate due to ovarian hyper stimulation syndrome (OHSS) (<xref rid="B7" ref-type="bibr">7</xref>). Given the fact that endogenous LH is already elevated in PCOS patients, the highly purified or recombinant FSH preparations are adopted presuming the theoretical advantage of better efficacy as well as lower OHSS rate (<xref rid="B12" ref-type="bibr">12</xref>-<xref rid="B14" ref-type="bibr">14</xref>). Furthermore, anti-estrogenic effects of CC with its main drawback of suppressed thin endometrium can be eliminated (<xref rid="B15" ref-type="bibr">15</xref>). Low dose FSH has been safely and effectively applied for OI in PCOS patients following failure with CC therapy (<xref rid="B16" ref-type="bibr">16</xref>-<xref rid="B21" ref-type="bibr">21</xref>).</p><p> Until now, two studies have looked into the use of low dose recombinant FSH as the first step for OI in PCOS women (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). In continuation to those trials, this study was designed to investigate the outcomes of recombinant human FSH usage as the first-line treatment of infertility in women with PCOS.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This study was a pilot double &#x02013; blind randomized clinical trial with registration number: 11135181N8 which was performed during a one-year period from March 2013 to June 2014 at the Infertility Clinic of Vali-e-Asr Research Centre known to be a referral infertility center in Tehran. The ethical approval was obtained from the Faculty of Medical Ethics Committee of Tehran University of Medical Sciences.</p><p>The H<sub>0</sub> or the null hypothesis of the study was that rFSH usage as the first-line treatment for the OI in PCOS was not associated with superior outcomes. The H<sub>1</sub> or the alternative hypothesis on the other hand was that rFSH would be more efficacious than CC for OI in PCOS patients in terms of reproductive outcomes. Due to the novelty of this study in our country, it was regarded to be a pilot study consisting of 60 subjects per each treatment arm evaluated for a single treatment course at the first step. </p><p> Block randomization method was chosen, i.e. using Stats Direct statistics software, random block size of between 4 to 8 was determined. Allocation proceeded by randomly selecting one of the orderings and assigning the next block of participants to study groups according to the specified sequence. This was done by a third person blind to the study. The investigators themselves were blind to the patients list. A total of 120 women with primary infertility, were enrolled in the study. </p><p>The inclusion criteria were as follows:</p><p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. The diagnosis of PCOS according to the revised Rotterdam criteria by the European Society for Human Reproduction / American Society of Reproductive Medicine infertility. 2. Age range of 18 to 40 years old. 3. BMI &#x02264; 30 kg/m2. </p><p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;The exclusion criteria were: </p><p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. History of previous infertility treatment. 2. Other infertility problems like endometriosis or male factor infertility. 3. Abnormal uterine cavity or tubes based on hysterosalpingography or laparoscopy. </p><p>Hormone profile including serum FSH, LH, PRL, AMH, estradiol, DHEAS, testosterone and 17OH-progesterone were measured for all the participants. Sixteen subjects were excluded with 12 not meeting the inclusion criteria and 4 refusing to participate. Finally, 104 subjects remained who were randomly assignedto receive either CC or recombinant FSH as their first treatment course.</p><p>
<bold><italic>Treatment protocol</italic></bold>
</p><p>In one arm, Clomiphene Citrate (Aboureyhan Co. Tehran, Iran) was given to 52 patients with the starting dose of 100 mg per day from day 3 of a spontaneous or progestin-induced menstruation for five consecutive days. In the other arm recombinant human FSH (Gonal-F, Merck Serono Co. Italy) with the starting dose of 50 IU was prescribed from cycle day 4. Weekly increase of 12.5 IU was done if necessary to induce the follicular response. Transvaginal sonography was done every other day from day 11 until at least one follicle &#x02265; 17 mm was seen; in that case, ovulation was induced by the administration of 10000 IU of human chorionic gonadotropin (hCG) and intercourse was recommended for the following two days.</p><p>Pregnant women underwent an ultrasound at 7 and 11 weeks of gestation. The pregnancies were classified as clinical or ongoing and singleton or multiple according to further sonography reports. Visualization of one or more gestational sacs was defined as clinical pregnancy. Ongoing pregnancy was defined if pregnancy continued for more than 20 completed weeks of gestation. </p><p>The patients were then followed until the end of the pregnancy.</p><p>
<bold><italic>Statistical analysis</italic></bold>
</p><p>Data was analyzed using SPSS software version 15. Chi-square, Student&#x02019;s t-test and Fischer&#x02019;s exact test were used to evaluate the differences between the groups. P value &#x0003c; 0.05 and confidence interval of 95% were considered to be statistically significant.</p><p>
<bold><italic>Ethical Considerations</italic></bold>
</p><p>Informed consent was obtained from all the participants.</p></sec><sec sec-type="results"><title>Results</title><p>All the subjects in the CC arm completed the treatment course and entered the analysis. Of 52 women who were about to receive Gonal-F, 5 quitted the study due to personal reasons. Of the remaining 47, 2 women changed their addresses and phone numbers and one became pregnant in the middle. Therefore, 44 subjects in this arm finally entered the analysis. The consort flow chart is illustrated in <xref ref-type="fig" rid="F1">figure 1</xref>. The demographic and clinical characteristics at the baseline were similar between the groups (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>As a whole, 11 clinical pregnancies (11.5%) were achieved. <xref ref-type="table" rid="T2">Table 2</xref> shows the results per each trial group. In the CC group, 5 clinical pregnancies were achieved (9.6%) and all led to live births. Four of women who became pregnant in this group, 80%, were younger than 30 years old.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow Diagram</p></caption><graphic xlink:href="JFRH-10-42-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline demographic and clinical characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4A6E62; color:#FFFFFF;" align="left" rowspan="1" colspan="1"/><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>All patients</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Gonal-F</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>CC</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>p-value</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Age (years)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">28.28 &#x000b1; 4.71 <xref ref-type="table-fn" rid="TFN1">a</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">27.52 &#x000b1; 4.76</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">29.18 &#x000b1; 4.52</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.084<xref ref-type="table-fn" rid="TFN2">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">25.09 &#x000b1; 3.65</td><td align="center" rowspan="1" colspan="1">25.21 &#x000b1; 3.54</td><td align="center" rowspan="1" colspan="1">24.95 &#x000b1; 3.82</td><td align="center" rowspan="1" colspan="1">0.733</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Infertility duration <xref ref-type="table-fn" rid="TFN3">c</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">2.76 &#x000b1; 1.69</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">2.57 &#x000b1; 1.65</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">2.97 &#x000b1; 1.73</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" rowspan="1" colspan="1">Menstrual duration <xref ref-type="table-fn" rid="TFN4">d</xref></td><td align="center" rowspan="1" colspan="1">6.61 &#x000b1; 6.24</td><td align="center" rowspan="1" colspan="1">6.15 &#x000b1; 1.37</td><td align="center" rowspan="1" colspan="1">7.16 &#x000b1; 9.13</td><td align="center" rowspan="1" colspan="1">0.435</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Menstrual interval <xref ref-type="table-fn" rid="TFN4">d</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">30.48 &#x000b1; 8.86</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">31.06 &#x000b1; 10.59</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">29.71 &#x000b1; 5.83</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.438</td></tr><tr><td align="left" colspan="5" rowspan="1">Hormonal profile</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">FSH <xref ref-type="table-fn" rid="TFN5">e</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">5.67 &#x000b1; 0.26</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">5.75 &#x000b1; 0.36</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">5.57 &#x000b1; 0.39</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.738</td></tr><tr><td align="left" rowspan="1" colspan="1">LH <xref ref-type="table-fn" rid="TFN5">e</xref></td><td align="center" rowspan="1" colspan="1">6.34 &#x000b1; 0.52</td><td align="center" rowspan="1" colspan="1">6.80 &#x000b1; 0.84</td><td align="center" rowspan="1" colspan="1">5.79 &#x000b1; 0.55</td><td align="center" rowspan="1" colspan="1">0.339</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">PRL <xref ref-type="table-fn" rid="TFN6">f</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">87.69 &#x000b1; 15.29</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">79.83 &#x000b1; 18.08</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">97.21 &#x000b1; 25.92</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.574</td></tr><tr><td align="left" rowspan="1" colspan="1">AMH <xref ref-type="table-fn" rid="TFN5">e</xref></td><td align="center" rowspan="1" colspan="1">5.55 &#x000b1; 0.56</td><td align="center" rowspan="1" colspan="1">5.19 &#x000b1; 0.62</td><td align="center" rowspan="1" colspan="1">5.97 &#x000b1; 0.98</td><td align="center" rowspan="1" colspan="1">0.494</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Estradiol <xref ref-type="table-fn" rid="TFN6">f</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">83.74 &#x000b1; 11.51</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">70.32 &#x000b1; 11.82</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">103.87 &#x000b1; 22.27</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.155</td></tr><tr><td align="left" rowspan="1" colspan="1">Progesterone <xref ref-type="table-fn" rid="TFN6">f</xref></td><td align="center" rowspan="1" colspan="1">1.47 &#x000b1; 0.14</td><td align="center" rowspan="1" colspan="1">1.63 &#x000b1; 0.06</td><td align="center" rowspan="1" colspan="1">1.30 &#x000b1; 0.26</td><td align="center" rowspan="1" colspan="1">0.289</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">DHEAS <xref ref-type="table-fn" rid="TFN6">f</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">98.82 &#x000b1; 12.16</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">85.90 &#x000b1; 14.03</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">114.62 &#x000b1; 20.79</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.242</td></tr><tr><td align="left" rowspan="1" colspan="1">Testosterone <xref ref-type="table-fn" rid="TFN6">f</xref></td><td align="center" rowspan="1" colspan="1">2.17 &#x000b1; 0.87</td><td align="center" rowspan="1" colspan="1">1.94 &#x000b1; 1.02</td><td align="center" rowspan="1" colspan="1">2.42 &#x000b1; 1.44</td><td align="center" rowspan="1" colspan="1">0.782</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p>: mean &#x000b1; SD; </p></fn><fn id="TFN2"><label>b</label><p>: student&#x02019;s t test; </p></fn><fn id="TFN3"><label>c</label><p>: years; </p></fn><fn id="TFN4"><label>d</label><p>: days; </p></fn><fn id="TFN5"><label>e</label><p>: IU/L; </p></fn><fn id="TFN6"><label>f</label><p>: ng/dl</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Morphologic ultrasound features following ovulation induction</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4A6E62; color:#FFFFFF;" align="left" rowspan="1" colspan="1"/><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>CC</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Gonal-F</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>p-value</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Right ovary</td><td align="center" colspan="3" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dominant follicles <xref ref-type="table-fn" rid="TFN7">a</xref></td><td align="center" rowspan="1" colspan="1">1 &#x000b1; 0.71 <xref ref-type="table-fn" rid="TFN8">b</xref></td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1; 1.17</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Follicular size <xref ref-type="table-fn" rid="TFN9">c</xref></td><td align="center" rowspan="1" colspan="1">13.95 &#x000b1; 8.13</td><td align="center" rowspan="1" colspan="1">14.55 &#x000b1; 6.70</td><td align="center" rowspan="1" colspan="1">0.697</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Left ovary</td><td style="background-color:#E6EED5;" align="center" colspan="3" rowspan="1"/></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dominant follicles</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">1.49 &#x000b1; 2.34</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">1.13 &#x000b1; 0.98</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.363</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Follicular size</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">13.49 &#x000b1; 7.64</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">11.9 &#x000b1; 8.32</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.339</td></tr><tr><td align="left" rowspan="1" colspan="1">Endometrial thickness<break/>(on the day of hCG injection)</td><td align="center" rowspan="1" colspan="1">7.95 &#x000b1; 1.99</td><td align="center" rowspan="1" colspan="1">8.03 &#x000b1; 2.05</td><td align="center" rowspan="1" colspan="1">0.851</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>a</label><p>: number; </p></fn><fn id="TFN8"><label>b</label><p>: mean &#x000b1; SD; </p></fn><fn id="TFN9"><label>c</label><p>: mm</p></fn></table-wrap-foot></table-wrap><p>In the Gonal-F group, 6 women became pregnant (13.6%) with 4 of them, 66%, younger than 30. Of the two pregnancies in those who were older than 30, one resulted in spontaneous abortion (2.3%). In the end, 5 successful deliveries were achieved in this group (11.4%).</p><p>The clinical pregnancy rate in the Gonal-F group and the CC group was 13.6% and 9.6% respectively and this difference was not significant (p = 0.538). The live birth rate was not significantly different between the groups either {11.4% versus 9.6%, p = 0.78} (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p>According to our results, the mean number of dominant follicles of the right ovary was significantly higher after the treatment with FSH in comparison with CC, 1.60 &#x000b1; 1.17 and 1 &#x000b1; 0.71 respectively (p = 0.004). However, this difference was not significant for the left ovary (p = 0.363). The differences in mean follicular size after induction and the endometrial thickness on the day of hCG injection in two groups were not significant (<xref ref-type="table" rid="T2">Table 2</xref>). Neither OHSS nor multiple gestations were detected during the treatment cycle. In the Gonal-F group, the mean duration of stimulation was 8.65 &#x000b1; 1.93 days with the minimum of 5 days and maximum of 15 days. Of the total of 46 patients in this group, the duration of stimulation was 8 days in 15 of them. The mean dose of Gonal-F prescribed was 430 &#x000b1; 96 IU.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Results comparing CC and Gonal-F</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4A6E62; color:#FFFFFF;" align="left" rowspan="1" colspan="1"/><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>CC</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Gonal-F</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>p-value</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Odd&#x02019;s ratio</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Confidence interval (95%)</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients per protocol</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Clinical pregnancy</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">5 (9.6%)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">6 (13.6%)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.538</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">1.484</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.42-5.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Ongoing pregnancy</td><td align="center" rowspan="1" colspan="1">5 (9.6%)</td><td align="center" rowspan="1" colspan="1">5 (11.4%)</td><td align="center" rowspan="1" colspan="1">0.780</td><td align="center" rowspan="1" colspan="1">1.205</td><td align="center" rowspan="1" colspan="1">0.325-4.68</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Miscarriage</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">1 (2.3%)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.274</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">1.203</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.978-4.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Live birth rate</td><td align="center" rowspan="1" colspan="1">5 (9.6%)</td><td align="center" rowspan="1" colspan="1">5 (11.4%)</td><td align="center" rowspan="1" colspan="1">0.780</td><td align="center" rowspan="1" colspan="1">1.203</td><td align="center" rowspan="1" colspan="1">0.325-4.68</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Cycle cancellation</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1"/><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1"/><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OHSS</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>It has been more than 50 years that CC is established as the first-line agent for OI in women with PCOS. It is believed to be more convenient and cost-efficient (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>).</p><p>Alternatives other than CC are aromatase inhibitors like letrozole which is considered to have more favorable ovarian and endometrial effects (<xref rid="B3" ref-type="bibr">3</xref>). Nonetheless, there are concerns regarding interruption with normal aromatase function in fetal tissues and hence the risk of birth defects with this oral agent (<xref rid="B22" ref-type="bibr">22</xref>). Other alternatives include insulin sensitizers and low dose gonadotropins. The application of low-dose gonadotropins for ovulation induction (OI) in infertile women with PCOS after failure of treatment with clomiphene citrate (CC) has become a common practice. PCOS constitutes 20-40% of the causes of female infertility (<xref rid="B23" ref-type="bibr">23</xref>); therefore, given the high prevalence of this disorder, first-line intervention for OI in this disorder is of paramount importance and a short term cost-effective treatment is demanded. There have been only two studies regarding the use of gonadotropins as the first-line strategy. In the first one published by Lopez et al (<xref rid="B18" ref-type="bibr">18</xref>), the cumulative pregnancy rate (CPR) in FSH group was comparable to those on CC treatment. In the second study by Homburg et al (<xref rid="B19" ref-type="bibr">19</xref>), however, the pregnancy rate (PR) was twice as high with low-dose recombinant FSH compared with CC. Furthermore, the cumulative clinical PR after 3 cycles was 52.1% for rFSH group compared with 41.2% for CC group. The cumulative LBR after 3 cycles was also higher for the FSH group (47.4% versus 36.9%). Although rFSH was associated with higher costs and less convenience, its use was justified as the first-line modality for ovulation induction in PCOS (<xref rid="B19" ref-type="bibr">19</xref>). According to our results, PR and LBR though apparently higher in the Gonal-F treatment group, were not different significantly (p &#x0003e; 0.05). The important point was nevertheless, the fact that in none of those who received Gonal-F, the cycle was cancelled and no case of OHSS happened. Moreover, of 6 pregnancies achieved in the Gonal-F group, all were singleton pregnancies. In the Homburg et al study, multiple pregnancy rate was 3.4%.</p><p>In the classic low dose regimen, the starting dose of 50-75 IU FSH is used for 7 to 14 days followed by weekly increment of 50% of the initial or the previous dose until the follicular development is initiated and this dosage is continued until the criteria for hCG administration is reached (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B21" ref-type="bibr">21</xref>). According to Homburg study, what is critical in determining the mono ovulation and consequently better results is the amount of dosage increment and not the staring one (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Based on previous studies no significant difference was seen between the dosage of 37.5 and 50 IU as the starter (<xref rid="B21" ref-type="bibr">21</xref>). In his study with the starting dose of 50 IU FSH, successful results were obtained: mono-follicular ovulation in 83 % of the 69 cycles and pregnancy rate of 80 %. Only one cycle was cancelled and only one set of twin pregnancy developed (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Of course, the induction protocol can be varied according to the demographic features of different populations (<xref rid="B21" ref-type="bibr">21</xref>), as in another study in Vietnam, the starting dose of 25 IU FSH for a minimum of 14 days and an incremental dose of 25 IU when needed was regarded to be safe and resulted in 62.1% uni-follicular development and 15.8% cancellation rate (<xref rid="B16" ref-type="bibr">16</xref>). </p><p>With the introduction of new Gonal-F pens in our country which are more user- friendly and make it feasible to have an increment of as low as 12.5 IU by a single click, the treatment protocol of our trial was designed. The starting dose was set to be 50 IU and the policy of increasing dose of 12.5 IU based on transvaginal sonographic monitoring was employed. This study presents the results of the first cycle of treatment only. Investigation on further cycles of treatment with more participants is under progress. Besides that, in continuation to the previous trials by Lopez and Homburg (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>), our goal was to further focus on recombinant FSH as the first-line agent for COI in PCOS women. We wanted to evaluate this presumption that instead of prescribing clomiphene first and then moving to FSH, by giving the FSH from the beginning we would reach better results in shorter time. The research hypothesis was that rFSH was better than CC in terms of efficiency. Contrary to our expectations, Gonal-F was not associated with superior outcomes and the research hypothesis was rejected. However, with smaller increments thanks to the newly designed pens, rFSH was safely used in PCOS patients even as their first treatment option without occurrence of OHSS or cancellation of the cycle.</p><p>Another point to be added is the better response of the right ovary compared to the left one following OI in the FSH group. The mean number of dominant follicles in the right ovary after induction with rFSH was significantly higher in comparison with CC. In other words, the right ovary responded better in the rFSH group. These findings were consistent with those of two other studies in which right ovarian responses were reported to be superior after stimulation with FSH compared with left ones (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Though histologically and embryologically similar, may be due to anatomical differences such as venous drainage, ovulation occurs more frequently in the right ovary (<xref rid="B24" ref-type="bibr">24</xref>).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Recombinant FSH and clomiphene citrate had similar efficacy for the first cycle of OI in PCOS patients according to our results. </p><p>The limitations of our study were the small number of patients evaluated and the assessment of only a single cycle of treatment. However, the safe usage of rFSH as the first-line treatment without occurrence of OHSS or the need for cancellation of the cycle was an invaluable positive aspect. Although it cannot be concluded from this study that recombinant FSH implication for the first cycle of OI in PCOS infertile women is superior to CC, considering the cumulative effects of gonadotropins, the authors believe that rFSH could be more efficacious than CC and yield in better results during 3-6 cycles of OI if more studies with larger study population be done.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the personnel of the Vali-e-Asr Reproductive Health Research Center for their sheer commitment to the execution of this project.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><collab>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</collab><article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome</article-title><source> Fertil Steril</source><year>2004</year><volume>81</volume><fpage>19</fpage><lpage>25</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghetti</surname><given-names>P</given-names></name><name><surname>Carmina</surname><given-names>E</given-names></name><name><surname>De</surname><given-names>Leo V</given-names></name><name><surname>Lanzone</surname><given-names>A</given-names></name><name><surname>Orio</surname><given-names>F</given-names></name><name><surname>Pasquali</surname><given-names>R</given-names></name></person-group><article-title>How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology</article-title><source> J Endocrinol Invest</source><year>2015</year><volume>38</volume><fpage>1025</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">25835559</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ESHRE</surname><given-names>Capri Workshop Group</given-names></name></person-group><article-title>Health and fertility in World Health Organization group 2 anovulatory women</article-title><source> Human Reproduction Update</source><year>2012</year><volume>18</volume><fpage>586</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">22611175</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>E</given-names></name><name><surname>Chard</surname><given-names>J</given-names></name><name><surname>James</surname><given-names>D</given-names></name><name><surname>Treasure</surname><given-names>T</given-names></name><name><surname>Guideline</surname><given-names>Development Group</given-names></name></person-group><article-title>Fertility (update): summary of NICE guidance</article-title><source> BMJ</source><year>2013</year><volume>346</volume><fpage>f650</fpage><pub-id pub-id-type="pmid">23427132</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><collab>Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</collab><article-title>Consensus on infertility treatment related to polycystic ovary syndrome</article-title><source> Hum Reprod</source><year>2008</year><volume>23</volume><fpage>462</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">18308833</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homburg</surname><given-names>R</given-names></name></person-group><article-title>Polycystic ovary syndrome</article-title><source> Best Pract Res Clin Obstet Gynaecol</source><year>2008</year><volume>22</volume><fpage>261</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">17804299</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahuis</surname><given-names>MJ</given-names></name><name><surname>Weiss</surname><given-names>NS</given-names></name><name><surname>Van</surname><given-names>der veen F</given-names></name><name><surname>Mol</surname><given-names>BW</given-names></name><name><surname>Hampes</surname><given-names>PG</given-names></name><name><surname>Oosterhuis</surname><given-names>J</given-names></name><etal/></person-group><article-title>The M-OVIN study: does switching treatment to FSH and / or IUI lead to higher pregnancy rates in a subset of women with world health organization type II anovulation not conceiving after six ovulatory cycles with clomiphene citrate &#x02013; a randomized controlled trial</article-title><source> BMC Women's Health</source><year>2013</year><volume>13</volume><fpage>42</fpage><pub-id pub-id-type="pmid">24160333</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanem</surname><given-names>ME</given-names></name><name><surname>Elboghady</surname><given-names>LA</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Gibreel</surname><given-names>A</given-names></name><name><surname>Houssen</surname><given-names>M</given-names></name><name><surname>Shaker</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial</article-title><source> J Assist Reprod Genet</source><year>2013</year><volume>30</volume><fpage>1477</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">24014214</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Habbema</surname><given-names>JD</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name></person-group><article-title>Characteristics of the best prognostic evidence: an example on prediction of outcome after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility</article-title><source> Semin Reprod Med</source><year>2003</year><volume>21</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">12806558</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palomba</surname><given-names>S</given-names></name><name><surname>Falbo</surname><given-names>A</given-names></name><name><surname>Zullo</surname><given-names>F</given-names></name></person-group><article-title>Management strategies for ovulation induction in women with polycystic ovary syndrom and known clomiphene citrate resistance</article-title><source> Curr Opin Obstet Gynecol</source><year>2009</year><volume>21</volume><fpage>465</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">19809318</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Farquhar</surname><given-names>C</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><name><surname>Boothroyd</surname><given-names>C</given-names></name><name><surname>Hughes</surname><given-names>E</given-names></name></person-group><article-title>Clomiphene and anti-estrogens for ovulation induction in PCOS</article-title><source> Cochrane Database Syst Rev</source><year>2009</year><issue>4</issue><fpage>CD002249</fpage><pub-id pub-id-type="pmid">19821295</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayram</surname><given-names>N</given-names></name><name><surname>vanWely</surname><given-names>M</given-names></name><name><surname>van</surname><given-names>Der Veen F</given-names></name></person-group><article-title>Recombinant FSH versus urinary gonadotropins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome</article-title><source> Cochrane Database Syst Rev</source><year>2001</year><issue>2</issue><fpage>CD002121</fpage><pub-id pub-id-type="pmid">11406034</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balen</surname><given-names>A</given-names></name></person-group><article-title>Ovulation induction for polycystic ovary syndrome</article-title><source> Hum Fertil (Camb)</source><year>2000</year><volume>3</volume><fpage>106</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11844364</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchard</surname><given-names>P</given-names></name></person-group><article-title>Treatment of infertility in women with polycystic ovary syndrome</article-title><source> Ann Endocrinol (Paris)</source><year>2010</year><volume>71</volume><fpage>225</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20394912</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homburg</surname><given-names>R</given-names></name><name><surname>Howles</surname><given-names>CM</given-names></name></person-group><article-title>Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements</article-title><source> Hum Reprod Update</source><year>1999</year><volume>5</volume><fpage>493</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10582786</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>VT</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name><name><surname>Nhu</surname><given-names>GH</given-names></name><name><surname>Tuan</surname><given-names>PH</given-names></name><name><surname>Tuong</surname><given-names>HM</given-names></name></person-group><article-title>Ovulation induction using low-dose step-up rFSH in Vietnamese women with polycystic ovary syndrome</article-title><source> Reprod Biomed Online</source><year>2009</year><volume>18</volume><fpage>516</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">19400993</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orvieto</surname><given-names>R</given-names></name><name><surname>Homburg</surname><given-names>R</given-names></name></person-group><article-title>Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy</article-title><source> Fertil Steril</source><year>2009</year><volume>91</volume><fpage>1533</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18990384</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>E</given-names></name><name><surname>Gunby</surname><given-names>J</given-names></name><name><surname>Daya</surname><given-names>S</given-names></name><name><surname>parrilla</surname><given-names>JJ</given-names></name><name><surname>Abad</surname><given-names>L</given-names></name><name><surname>Balasch</surname><given-names>J</given-names></name></person-group><article-title>Ovulation induction in women with polycystic ovarian syndrome: randomized trial of clomiphene citrate versus low dose recombinant FSH as first line therapy</article-title><source> Reprod Biomed Online</source><year>2004</year><volume>9</volume><fpage>382</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15511336</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homburg</surname><given-names>R</given-names></name><name><surname>Hendriks</surname><given-names>ML</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>TE</given-names></name><name><surname>Anderson</surname><given-names>RA</given-names></name><name><surname>Balen</surname><given-names>AH</given-names></name><name><surname>Brincat</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clomiphene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study</article-title><source> Hum Reprod</source><year>2012</year><volume>27</volume><fpage>468</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">22128296</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spritzer</surname><given-names>PM</given-names></name><name><surname>Motta</surname><given-names>AB</given-names></name><name><surname>Sir-Petermann</surname><given-names>T</given-names></name><name><surname>Diamanti-Kandarakis</surname><given-names>E</given-names></name></person-group><article-title>Novel strategies in the management of polycystic ovary syndrome</article-title><source> Minerva Endocrinol</source><year>2015</year><volume>40</volume><fpage>195</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">25781065</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homburg</surname><given-names>R</given-names></name></person-group><article-title>Ovulation Induction and Controlled Ovarian Stimulation</article-title><source> Springer International Publishing Switzerland</source><year>2014</year><volume>chapter. 9</volume><fpage>87</fpage><lpage>95</lpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazarganipour</surname><given-names>F</given-names></name><name><surname>Taghavi</surname><given-names>SA</given-names></name><name><surname>Montazeri</surname><given-names>A</given-names></name><name><surname>Ahmadi</surname><given-names>F</given-names></name><name><surname>Chaman</surname><given-names>R</given-names></name><name><surname>Khosravi</surname><given-names>A</given-names></name></person-group><article-title>The impact of polycystic ovary syndrome on the health-related quality of life: A systematic review and meta-analysis</article-title><source> Iran JReprod Med</source><year>2015</year><volume>13</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">25999994</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biljan</surname><given-names>MM</given-names></name><name><surname>Hemmings</surname><given-names>R</given-names></name><name><surname>Brassard</surname><given-names>N</given-names></name></person-group><article-title>The Outcome of 150 Babies Following the Treatment WithLetrozole or Letrozole and Gonadotropins</article-title><source> Fertility and Sterility</source><year>2005</year><volume>84</volume><fpage>S95</fpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>KC</given-names></name><name><surname>Huang</surname><given-names>FJ</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Kung</surname><given-names>FT</given-names></name><name><surname>Lan</surname><given-names>TH</given-names></name><name><surname>Chang</surname><given-names>SY</given-names></name></person-group><article-title>Significantly superiorresponse in the right ovary compared with the left ovary after stimulation withfollicle-stimulating hormone in a pituitary down-regulation regimen</article-title><source> Fertil steril</source><year>2010</year><volume>93</volume><fpage>2269</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">19200958</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>AJ</given-names></name><name><surname>Gazvani</surname><given-names>MR</given-names></name><name><surname>Wood</surname><given-names>SJ</given-names></name><name><surname>Meacock</surname><given-names>SC</given-names></name><name><surname>Lewis-Jones</surname><given-names>DI</given-names></name><name><surname>Kingsland</surname><given-names>CR</given-names></name></person-group><article-title>Comparison of ovarian response in right and left ovaries in IVF patients</article-title><source> Hum Reprod</source><year>2001</year><volume>16</volume><fpage>1694</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11473965</pub-id></element-citation></ref></ref-list></back></article>